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Heteroallelic proteinHybrid forms of human phenylalanine hydroxylase (hPAH) mutants have been found to present catalytic
activities lower than predicted from the individual recombinant forms, indicating that interallelic
complementation could be a major determinant of the metabolic phenotype of compound heterozygous
phenylketonuric (PKU) patients. To provide a molecular explanation for interallelic complementation we
have here developed a bicistronic expression system and a puriﬁcation strategy to obtain isolated hPAH
heteromeric forms. On co-expression of WT-hPAH (~50% tetramer; ~10% dimer) and the N- and C-terminally
truncated form ΔN102/ΔC24-hPAH (~80% dimer) no heterodimers were recovered. Moreover, by co-
expression of WT-hPAH and the N-terminally truncated form ΔN102-hPAH (~95% tetramer), heterote-
tramers, as a result of an assembly of two different homodimers, were isolated. The recovered (WT)/(ΔN102)-
hPAH heterotetramers revealed a catalytic activity deviating signiﬁcantly from that calculated by averaging
the respective recombinant homotetrameric forms. The heterotetramer assembly also results in conforma-
tional changes in the WT-hPAH protomer, as detected by trypsin limited proteolysis. The ﬁnding that the
presence of two homodimers with different kinetic parameters inﬂuences the properties of the resulting
heterotetrameric protein indicates that the dimers exhibit interactions which are transmitted across the
assembled tetramer. The bicistronic expression system developed here allowed the isolation of hybrid forms
that exhibit negative interallelic complementation, and may represent a model system for studying the
molecular pathogenic mechanisms of PAH gene mutations in compound heterozygous PKU patients,
providing the rationale to understand the observed inconsistencies both in genotype/phenotype correlations
and in the response to BH4 supplementation.rythro-5,6,7,8-tetrahydrobiop-
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Human phenylalanine hydroxylase (hPAH, human phenylalanine
4-monooxygenase, EC 1.14.16.1), is a non-heme iron enzyme that
catalyzes the hydroxylation of L-phenylalanine (L-Phe) to L-tyrosine
(L-Tyr) in the presence of the cofactor (6R)-L-erythro-5,6,7,8-tetra-
hydrobiopterin (BH4) and dioxygen, the rate-limiting step in L-Phe
catabolism [1]. hPAH is a homotetrameric/homodimeric protein with
the protomer organized into three functional domains: a regulatory
N-terminal domain (residues 1–117) containing the phosphorylation
site (Ser16) and an autoregulatory sequence (ARS, residues 1–33); acatalytic core domain (residues 118–411); and a C-terminal region
(residues 412–452) including the dimerization and tetramerization
motifs [1,2]. The tetramer is a dimer of two conformationally different
dimers, related by a 2-fold noncrystallographic symmetry axis [3]. It is
activated 5- to 6-fold on preincubation with L-Phe, reveals a positive
kinetic cooperativity with respect to L-Phe and Michaelis–Menten
kinetics with BH4 for the non-preactivated enzyme [4] and BH4-
dependent positive cooperativity for the preactivated form [5].
Mutations in hPAH causing lost or impaired activity of the enzyme
are associated with the autosomal recessively inherited disease
phenylketonuria (PKU, OMIM 261600), the most frequent disorder
of amino acid metabolism [6], with a high genotypic heterogeneity
(more than 500 different PAH gene mutations identiﬁed to date;
http://www.pahdb.mcgill.ca [7]). If untreated, PKU patients present
neurological damages due to the increased levels of L-Phe in body
ﬂuids [8], and life-long dietary restriction of L-Phe remains the most
effective treatment for PKU [9]. Some PKU patients respond to oral
ingestion of the pterin cofactor (BH4) by a reduction in blood L-Phe
concentration (BH4-responsive) and therefore, presently BH4 is
accepted as a novel therapeutic approach. However, it has been
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phenotype [10–12].
A unique property of homomeric enzymes associated with
human genetic disorders is their potential ability to exhibit
interallelic complementation (IC), a phenomenon that occurs in
heteroallelic states when particular combinations of two different
alleles, at a given locus, produce a less (positive IC) or a more
(negative IC) severe phenotype than their homoallelic counter-
parts. IC is observed in homomeric enzymes where the protomers
exhibit interactions resulting in hybrid proteins with functional or
stability properties signiﬁcantly different from the average of the
parental enzymes. The phenomenon is proposed to contribute to
the phenotypic diversity of several human diseases including
metabolic disorders such as PKU [13,14], argininosuccinic aciduria
[15–17], erythropoietic protoporphyria [18] and galactosemia
[19,20], neurodegenerative disorders such as familial amyloid
polyneuropathy [21,22] and cancer [23,24]. Interallelic comple-
mentation is assumed to be of particular importance in PKU since
~75% of PKU patients are compound heterozygous, encoding two
different mutant hPAH protomers [25]. Experimental evidence
lending support to a negative IC in some compound heterozygous
PKU patients has been obtained by the observations that the
patients present: (i) a more severe metabolic phenotype than that
anticipated by the predicted residual activity (PRA) based on in
vitro assays of recombinant proteins [26–28], and (ii) an absence
or only a partial response to BH4, although carrying two BH4-
responsive alleles [29]. Interactions between different hPAH
protomers have been demonstrated by three different experimen-
tal strategies, i.e. in vitro formation of heterotetramers from
different dimers [30], the yeast two-hybrid system [31] and a
dual vector prokaryotic expression system producing two different
hPAH subunits mimicking the natural heteroallelic state in
heterozygous or in compound heterozygous patients [14]. Howev-
er, the molecular mechanism of negative IC and its role in PKU
pathogenesis is far from being solved since heterotetrameric forms
of hPAH have only been demonstrated in vitro [30], but never
isolated and characterized biochemically.
In order to provide some insight into the assembly process of
heteroallelic hPAH proteins and their non-additive gene dosage
effect, truncated forms of the protein (ΔN102-hPAH and ΔN102/
ΔC24-hPAH) were co-expressed with WT-hPAH, and the hetero-
meric forms characterized biochemically. To isolate the recombinant
heteromeric proteins in high yield and purity a bicistronic
expression system was developed, presenting the different proto-
mers as fusion proteins with the chaperone maltose binding protein
(MBP) [30,32] and different afﬁnity puriﬁcation tags (calmodulin
binding peptide (CBP), hexahistidyl peptide (6His) and StrepII
peptide). The afﬁnity isolated heteromeric species were character-
ized by their steady-state kinetic properties and susceptibility to
limited proteolysis.
2. Materials and methods
2.1. Materials
The DNA primers used for mutagenesis were provided by
Eurogentec (Seraing, Belgium) and the restriction endonucleases
were fromNew England Biolabs (USA). Escherichia coli BL21(DE3) and
the prokaryotic expression vector pETDuet-1 were obtained from
Novagen (Merck KGaA, Darmstadt, Germany). The restriction prote-
ase factor Xa was obtained from Protein Engineering Technology ApS
(Aarhus, Denmark). SDS molecular mass standard was delivered by
Bio-Rad and the pterin cofactor (6R)-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4) was obtained from Schircks Laboratories (Jona,
Switzerland). Trypsin and trypsin inhibitor were delivered by
Sigma-Aldrich (St. Louis, MO, USA).2.2. Construction of the bicistronic expression vectors
The calmodulin binding peptide (later replaced by the StrepII
sequence) and the hexahistidyl peptide (6His; HHHHHH) were ﬁrstly
selected to produce different N-terminal tagged recombinant proteins
using the bicistronic expression vector pETDuet-1. This vector
contains two multiple cloning sites (MCS1 and MCS2), each preceded
by a T7 promoter/lac operator and a ribosome binding site. A T7
terminator sequence is located at 3′ of the MCS2.
The strategy to construct the bicistronic expression vector is
depicted in Supplementary Fig. S1. The sequence coding for the
calmodulin binding peptide (CBP; KRRWKKNFIAVSAANRFKKISSS-
GAL) together with a PmeI restriction sequence were introduced 5′
to the MBP coding sequence by three steps of site-directed
mutagenesis using the pMAL-hPAH vector as a template [33] and
primers CBP1st-F/CBP1st-R, CBP2nd-F/CBP2nd-R and CBP3rd-F/
CBP3rd-R (Table 1). The resulting vector pMAL-CBP-MBP-pep(Xa)-
WT-hPAH was double digested with PmeI/SbfI. The isolated expres-
sion cassette was blunted with T4 DNA polymerase, according to
standard procedures, and cloned into the MCS1 of pETDuet-1 vector
which had been previously digested with NcoI, blunted and depho-
sphorylated with calf intestinal alkaline phosphatase (CIP), thus
generating the expression vector pETDuet-1-CBP-MBP-pep(Xa)-WT-
hPAH.
In order to replace the CBP tag by the StrepII tag (WSHPQFEK), two
steps of site-directed mutagenesis were performed using the
pETDuet-1-CBP-MBP-pep(Xa)-WT-hPAH as template and primers
STRII-F/STRII-R and CBPDel-F/CBPDel-R (Table 1). In the obtained
construct (pETDuet-1-StrepII-MBP-pep(Xa)-WT-hPAH) a new T7
terminator was introduced 3′ to MCS1, by site-directed mutagenesis,
using primers CRET7-F/CRET7-R (Table 1).
To create the bicistronic expression construct the sequence coding
for the 6His tag and the PmeI restriction sequence were previously
introduced 5′ to theMBP coding sequence by site-directedmutagenesis,
using pMAL-MBP-pep(Xa)-ΔN102-hPAH or pMAL-MBP-pep(Xa)-ΔN102/
ΔC24-hPAH constructs as templates [34] and primers HisF/HisR
(Table 1). The expression cassette was isolated, after PmeI/SbfI double
digestion, blunt-ended and cloned into the MCS2 of pETDuet-1-StrepII-
MBP-pep(Xa)-WT-hPAH vector which had been previously digested
with EcoRV (MCS2), blunt-ended and dephosphorylated. The pETDuet-
1-[StrepII-MBP-pep(Xa)-WT-hPAH/6His-MBP-pep(Xa)-ΔN102-hPAH]
and pETDuet-1-[StrepII-MBP-pep(Xa)-WT-hPAH/6His-MBP-pep(Xa)-
ΔN102/ΔC24-hPAH] bicistronic constructs were obtained (Fig. 1).
Site-directed mutagenesis reactions were always performed using the
Quikchange® II XL system (Stratagene, La Jolla, CA, USA) and the
authenticity of mutagenesis reactions and cloning was always veriﬁed
by DNA sequencing using the BigDye® Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) in an ABI 3730xl DNA Analyzer
(Applied Biosystems). All the expression constructs present a cleavage
site for factor Xa (IEGR) between the N-terminal fusion protein and the
hPAH sequence.
2.3. Expression and puriﬁcation of recombinant hPAH
E. coli BL21(DE3) competent cells were transformed with the
pETDuet-1-[StrepII-MBP-pep(Xa)-hPAH1/6His-MBP-pep(Xa)-hPAH2]
(hPAH1: WT-hPAH; hPAH2: ΔN102-hPAH or ΔN102/ΔC24-hPAH)
expression vectors and grown in LB medium, supplemented with
50 μg⋅mL−1 ampicillin and 0.2% glucose, at 37 °C. Protein expression
was induced with 1 mM isopropyl thio-β-D-galactoside (IPTG),
when the A600 was about 0.8. Ferrous ammonium sulfate, at
0.2 mM, was added simultaneously with IPTG and 3 h after
induction. After 8 h incubation, at 28 °C, bacteria were harvested
and the pellets stored at −20 °C until use. To rule out homologous
recombination, plasmid integrity was checked. To purify the
recombinant enzymes, cells were resuspended in lysis buffer
Table 1
Oligonucleotides used for site-directed mutagenesis.
Template Primersa Sequence (5′→3′)b
pMAL-hPAHwt CBP1st F CCAACAAGGACCATAGATTATGGTTTAAACTTAAGCGACGATGGAAAAAGAAAAATCGAAGAAGGTAAACTGG
CBP1st R CCAGTTTACCTTCTTCGATTTTTCTTTTTCCATCGTCGCTTAAGTTTAAACCATAATCTATGGTCCTTGTTGG
pMAL-CBP1-hPAHwt CBP2nd F CTTAAGCGACGATGGAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCAAAATCGAAGAAGGTAAACTGG
CBP2nd R CCAGTTTACCTTCTTCGATTTTGCGGTTGGCTGCTGAGACGGCTATGAAATTCTTTTTCCATCGTCGCTTAAG
pMAL-CBP2-hPAHwt CBP3rd F GCCGTCTCAGCAGCCAACCGCTTTAAGAAAATCTCATCCTCCGGGGCACTTAAAATCGAAGAAGGTAAACTGG
CBP3rd R CCAGTTTACCTTCTTCGATTTTAAGTGCCCCGGAGGATGAGATTTTCTTAAAGCGGTTGGCTGCTGAGACGGC
pETDuet-1-CBP-hPAHwt STRII F GAAAATCTCATCCTCCGGGGCACTTGCTAGCTGGAGCCACCCGCAGTTCGAAAAAGGCAGCAAAATCGAAGAAGGTAAACTGG
STRII R CCAGTTTACCTTCTTCGATTTTGCTGCCTTTTTCGAACTGCGGGTGGCTCCAGCTAGCAAGTGCCCCGGAGGATGAGATTTTC
pETDuet-1-CBP-STRII-hPAHwt CBPDel F CAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGCTAGCTGGAGCCACCCGCAGTTCGAAAAA
GGCAGCAAAATCGAAGAAGG
CBPDel R CCTTCTTCGATTTTGCTGCCTTTTTCGAACTGCGGGTGGCTCCAGCTAGCCATGGTATATCTCCTTCTTAAAGTTAAACAAAAT
TATTTCTAGAGGGGAATTG
pETDuet-1-STRII-hPAHwt CRET7T F GCAGGTCGACAAGCTTGCGGCCGCATAATGCTTCTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG
AAGTCGAACAGAAAGTAATCGTATTGTACACG
CRET7T R CGTGTACAATACGATTACTTTCTGTTCGACTTCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAG
AAGCATTATGCGGCCGCAAGCTTGTCGACCTGC
pMAL-hPAHΔN102 and
pMAL-hPAHΔN102/ΔC24
HIS F CCAACAAGGACCATAGATTATGGTTTAAACCATCACCATCACCATCACAAAATCGAAGAAGGTAAACTGG
HIS R CCAGTTTACCTTCTTCGATTTTGTGATGGTGATGGTGATGGTTTAAACCATAATCTATGGTCCTTGTTGG
a F—forward, R—reverse.
b Mismatch nucleotides are shown in boldface; nucleotides used to create new restrictions sites are underlined.
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supplemented with 1× Complete Protease Inhibitor Cocktail (Roche
Applied Science) and disrupted by passage through a French Press.
The presence of the MBP tag, in both hPAH subunits, allowed the
puriﬁcation of the fusion proteins using an amylose resin (New
England Biolabs), previously equilibrated with 15 mM Na–Hepes,
200 mM NaCl, and 1 mM EDTA, pH 7.4. Recombinant proteins were
eluted with 10 mM maltose [33].
The tetramers and dimers were isolated by size-exclusion
chromatography (SEC), using a HiLoad Superdex 200 HR columnA
B
WT-hPAH
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Fig. 1. Schematic representation of the bicistronic expression construct and the hPAH
polypeptide chains used to study interallelic complementation. (A) pETDuet-1
expression construct carrying two expression cassettes each under the control of a
T7 lac promoter (T7lac-1 and T7lac-2) and presenting a T7 polymerase termination site
(T7T); the hPAH1 polypeptide chain is expressed as a fusion protein with the StrepII tag
(StrepII) and the maltose binding protein (MBP) and the hPAH2 polypeptide chain is
expressed as a fusion protein with the hexahistidyl tag (6His) and MBP; pep(Xa)
represents the sequence encoding the factor Xa protease cleavage site. (B) Schematic
illustration of the structure of wild-type (WT-hPAH) and truncated forms (ΔN102-
hPAH and ΔN102/ΔC24-hPAH) of hPAH with the regulatory (RD), catalytic (CD) and
oligomerization (OD) domains represented; the residue number of the last amino acid
in each domain is indicated.(1.6 cm×60 cm, Amersham Biosciences) and a mobile phase contain-
ing 20 mM Na–Hepes, 200 mM NaCl, pH 7.0 (SEC buffer) pumped at a
ﬂow rate of 0.38 mL⋅min−1. The relative molecular mass of the
different oligomeric forms was estimated from a calibration curve
obtained with the following standard proteins: aprotinin (6.5 kDa),
ribonuclease A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin
(43 kDa), BSA (66 and 132 kDa), conalbumin (75 kDa), aldolase
(158 kDa), ferritin (440 kDa) and thyroglobulin (669 kDa). Blue
Dextran 2000 and AMP were used to determine the void volume
(V0=45.2 mL) and the total exclusion volume (VT=115.5 mL) of the
column, respectively. All puriﬁcation steps were carried out at 4 °C.
The relative amounts of the different oligomeric states were
calculated by deconvolution of the obtained chromatograms using
the PeakFit software (Systat Software Inc). Protein concentration was
estimated by the Bradford method [35] using bovine serum albumin
(BSA) as the standard.2.4. Isolation of hybrid proteins
The tetrameric or dimeric fractions obtained from SEC were
applied to a Ni-chelating resin (Ni–NTA, Qiagen, Valencia, CA), pre-
equilibrated in SEC buffer containing 10 mM imidazole, and stirred for
1 h at 4 °C. The ﬂow-through was collected (Fraction 1: StrepII-MBP-
hPAH1 homomeric proteins) and the resin was washed with SEC
buffer containing 20 mM imidazole, followed by a SEC buffer washing
step containing 50 mM imidazole. The fusion proteins were eluted
with SEC buffer containing 150 mM imidazole (Fraction 2: 6His-MBP-
hPAH2 homomeric and StrepII-MBP-hPAH1/6His-MBP-hPAH2 hetero-
meric proteins).
Fraction 2 was then applied to a Strep-Tactin resin (Strep-Tactin
Superﬂow high capacity, IBA, Göttingen, Germany) and stirred for 1 h
at 4 °C. The ﬂow-through was collected (Fraction 3: 6His-MBP-hPAH2
homomeric proteins) and the resin was washed with SEC buffer. The
hybrid proteins were eluted with SEC buffer containing 2.5 mM
desthiobiotin (Fraction 4: StrepII-MBP-hPAH1/6His-MBP-hPAH2 het-
eromeric proteins).
The fusion proteins obtained in Fractions 1, 3 and 4 were cleaved
for 4 h at 4 °C by factor Xa (Protein Engineering Technology ApS),
using a protease to substrate ratio of 1:30 (by mass), and applied to a
second column of amylose resin, to removeMBP, followed by removal
of factor Xa protease using the Xa Removal Resin (QIAGEN). The
homomeric hPAH1 and hPAH2 and the heteromeric hPAH1/hPAH2
forms were then obtained.
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acrylamide gels. The gels were stained by 0.1% (w/v) Coomassie
Brilliant Blue R250 (Bio-Rad) in 50% (v/v) methanol and 10% (v/v)
acetic acid. Stained gels were scanned using VersaDoc 4000 (Bio-Rad)
and the protein bands were quantiﬁed using the Quantity One 1-D
Analysis Software (Bio-Rad).
2.5. Assay of enzymatic activity
The hPAH activity was assayed essentially as described [33], using
0.1 mg⋅mL−1 of catalase and an enzyme activation step by prior
incubation (5 min) with L-Phe. BSA, at 0.5% (w/v), was included in the
reaction mixture to stabilize the diluted puriﬁed hPAH preparations.
The amount of L-Tyr formed after 1 min was measured by HPLC and
ﬂuorimetric detection [36]. The steady-state kinetic data were
analyzed by nonlinear regression analysis using the SigmaPlot®
Technical Graphing Software and the modiﬁed Hill equation of LiCata
and Allewel [37] for cooperative substrate binding as well as substrate
inhibition [38]. In order to study the effect of preincubationwith L-Phe
on the speciﬁc activity, 1 mM L-Phe was added together with 75 μM
BH4 at the initiation of the hydroxylation reaction. In this case a 3 min
time course was then followed.
2.6. Limited proteolysis with trypsin
Limited proteolysis of WT, ΔN102 and (WT)/(DN102)-hPAH
tetrameric forms was performed at 25 °C in 20 mM Na–Hepes,
200 mM NaCl, pH 7.0 and a protease to hPAH ratio of 1:200 (byStrepII MBP pep(Xa) hPAH1
6His MBP pep(Xa) hPAH2
Amylose affinity
purification
Size Exclusion
Chromatography
or
6His 
Purification
(Ni-NTA)
FT
Homotetramers
hPAH1
Tetrameric Fraction Dimeric Fraction
or
Ho
    
or
Fig. 2. Flow-chart of the puriﬁcation procedure of recombinantly co-expressed hPAH polype
different hPAH proteins was applied to an amylose resin in the ﬁrst puriﬁcation step. TheMBP
The tetrameric (or dimeric) fraction recovered was applied to a Ni–NTA resin. The StrepII tag
6His tagged homotetramers (or homodimers) and StrepII/6His tagged heterotetramers (or h
fraction was applied to a Strep-Tactin resin. The 6His tagged homotetramers (or homo
heterodimers) were eluted with desthiobiotin. This procedure resulted in the separation of t
and heteromeric StrepII/6His tagged.mass) in the absence or presence of 1 mM L-Phe. The ﬁnal protein
concentration was 0.3 mg⋅mL−1. At timed intervals (0–60 min)
aliquots of the reaction were mixed with soybean trypsin inhibitor
(at 1:1.5 (by mass) protease to inhibitor ratio) and subjected to SDS-
PAGE analysis. Gels were stained by Coomassie brilliant blue and the
band corresponding to the full-length protein was quantiﬁed by
densitometry.
3. Results
3.1. Co-expression of hybrid hPAH proteins using a bicistronic expression
system
Using a dual vector expression system encoding two different
epitopes (Myc and Xpress) we have previously shown the presence of
assembled hybrid hPAH proteins presenting a catalytic activity lower
than the PRA [14]. In theory ﬁve different tetrameric species would be
formed, from the combination of two different co-expressed hPAH
subunits (hPAH1:hPAH2), in the following ratios: 0:4, 1:3, 2:2, 3:1 and
4:0. However, by performing a cross-linking reaction of the co-
expressed Myc-WT-hPAH and Xpress-WT-hPAH prior to the co-
immunoprecipitation step, heterotetramers but not heterodimers
were detected in the immunoblots (R. Almeida, J. Leandro et al.,
personal communication). The absence of heterodimers indicates that
the heterotetrameric species 1:3 and 3:1 (hPAH1:hPAH2) would not
be formed and only the heterotetrameric 2hPAH1:2hPAH2 will be
expected, as represented in Fig. 2. Nevertheless, using the described
dual expression system [14], the low yields of obtained hybridImidazole
elution
StrepII 
Purification
(StrepTactin)
Desthiobiotin
elution
Heterotetramers 
  hPAH1/hPAH2
FT
modimers
  hPAH1 
or
Homotetramers
        hPAH2
or
Homodimers
      hPAH2 
or
  Heterodimers
  hPAH1/hPAH2
ptide chains (hPAH1 and hPAH2). The supernatant of lysed bacteria co-expressing two
fusion proteins were elutedwithmaltose and applied to a size-exclusion column (SEC).
ged homotetramers (or homodimers) were collected in the ﬂow-through (FT) and the
eterodimers) bound to the resin were eluted with imidazole. In the last step, the eluted
dimers) were obtained in the FT and the StrepII/6His tagged heterotetramers (or
hree different hPAH protein species: homomeric StrepII tagged, homomeric 6His tagged
606 J. Leandro et al. / Biochimica et Biophysica Acta 1812 (2011) 602–612proteins precluded the isolation of heteromeric recombinant enzymes
for further biochemical and structural characterization. To overcome
this problem, we developed here a bicistronic expression strategy,
where in addition to two different puriﬁcation tags (CBP or StrepII,
and 6His), the putative molecular chaperone maltose binding protein
was used as fusion partner, N-terminally to the hPAH protein, as
outlined in Fig. 1A. The presence of two different puriﬁcation tags
offers the possibility to obtain pure hetero-oligomeric fractions by
performing two afﬁnity-chromatographic steps (Fig. 2). MBP was
chosen as fusion partner (common to both polypeptides), as MBP has
been shown to have a chaperone like effect [32,39], improving the
yield of recombinant hPAH [30,33]. Using this strategy the WT-hPAH
(~50 kDa subunit) was co-expressed with truncated forms of hPAH
(Fig. 1B), namely the ΔN102-hPAH (~38.8 kDa subunit) which lacks
the ﬁrst 102 residues (corresponding to the N-regulatory domain)
and is mainly expressed as a tetramer (96%) (Table 2); and the double
truncated form ΔN102/ΔC24-hPAH (~36.2 kDa subunit) which also
lacks the 24 C-terminal residues (corresponding to the tetrameriza-
tion motif) and is mainly expressed as a dimer (81%) (Table 2). The
rationale for co-expressing the WT-hPAH with the truncated forms
was fourfold. First, co-expressing the WT-hPAH with the double
truncated form (which is isolated mainly as dimer), will expectedly
favor the assembly of a heterodimer and thus the presence/absence of
these species will allow us to refute/validate our previous observa-
tions concerning the assembly of heterodimers (R. Almeida, J. Leandro
et al., personal communication). Secondly, co-expressing the WT-
hPAH with the N-terminally truncated form (which is isolated mainly
as tetramer) will favor the assembly of a heterotetramer. Thirdly, due
to the different catalytic properties of the wild-type and truncated
forms [2,34] the impact of protomer interactions on the kinetic
properties of the assembled heteromeric forms will be proﬁciently
assessed. Fourthly, using SDS-PAGE analysis a clear distinction and
quantiﬁcation of the ratio of the different subunits will be possible
since the truncated forms present molecular masses lower than the
wild-type.
Small tags characterized by a high speciﬁcity and mild elution
conditions (Supplementary Table S1) were selected. The polyhistidine
tag was our ﬁrst choice since we had already used it to express and
purify recombinant hPAHs [40]. The choice of the second afﬁnity tag
was more challenging given the large number of alternatives [41,42].Table 2
Subunit molecular mass, major oligomeric forms, apparent molecular mass and relative
amounts of the hPAH fusion protein forms used in this study.
Expressed or
co-expressed
fusion proteins
Subunit molecular
mass (fusion
protein)a (kDa)
Oligomeric
state
Apparent
molecular
massb
Relative
amountsb,c
WT-hPAH 95.6 Aggregated − (40%)
Tetramer 371 kDa (52%)
Dimer 205 kDa (8%)
ΔN102-hPAH 84.4 Tetramer 310 kDa (96%)d
ΔN102/
ΔC24-hPAH
81.8 Aggregated − (17%)d
Dimer 156 kDa (81%)d
(WT)/
(ΔN102)-hPAH
95.6/84.4 Aggregated − (9%)
Tetramers −e (62%)
Dimer 219 kDa (12%)
(WT)/(ΔN102/
ΔC24)-hPAH
95.6/81.8 Aggregated − (20%)
Tetramer 412 kDa (14%)
Dimers −e (55%)
a Subunit molecular mass calculated from the amino acid sequence.
b The apparent molecular mass of the oligomeric forms and their relative amounts
were calculated by deconvolution analysis of the size-exclusion chromatograms using
the PeakFit software (Systat Software Inc) of the MBP-fusions proteins before Ni–NTA
and Strep-Tactin puriﬁcation.
c Degradation products not included.
d Data from [34].
e Apparent molecular mass not determined, as the broad peak correspondent to 2 or
more different species.As a ﬁrst candidate we tested the CBP peptide. However, during the
puriﬁcation process the hPAH polypeptide, preceded by the CBP tag
(CBP-MBP-pep(Xa)-hPAH1), suffered extensive aggregation as the
result of the effect of a highly hydrophobic patch, present in the
middle of the CBP tag (Supplementary Fig. S2). This aggregation was
not overcome by the use of glycerol (10%), or by the mild non-ionic
detergent n-octylglucoside (15 mM) nor by the use of the improved E.
coli C41(DE3) strain [43,44] (data not shown). Hence, the CBP tag was
replaced by the StrepII tag which allowed the recovery of soluble
hPAH in high yields. Since the original pETDuet-1 vector presents only
one T7 terminator after MCS2, a new T7 terminator was introduced
after MCS1 (Fig. 1A), in order to guarantee the existence of just two
mRNAs, each one corresponding to the transcribed sequence of the
two different hPAH cDNAs.
The expression conditions (28 °C, 1 mM IPTG, 8 h) were chosen in
a compromise between the maximum total recombinant protein
produced, its amount in the soluble fraction and the minimization of
hPAH deamidation that occurs with long induction times [45]. The
expression of the recombinant hPAHs asMBP-fusion proteins resulted
in high yields (~12 mg/L culture) when compared with the values
obtainedwith the dual expression system used in our previous studies
(~0.3 mg of fusion protein/L culture [14]). After the introduction of
the new T7 terminator similar levels of the translated proteins were
produced, as shown by SDS-PAGE analysis of the co-expressed
proteins after amylose afﬁnity puriﬁcation (Supplementary Fig. S3).
The double truncated dimer ΔN102/ΔC24-hPAH was an exception
since it was recovered in the soluble (Supplementary Fig. S3B, lane 3)
and dimeric fractions at higher levels due to its higher solubility. As
expected, on size-exclusion chromatography the separately expressed
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH were recovered
mainly in the tetrameric form whereas the double truncated 6His-
MBP-ΔN102/ΔC24-hPAH was recovered as a dimer (Table 2). Ac-
cordingly, for the co-expressed StrepII-MBP-WT-hPAH and 6His-
MBP-ΔN102/ΔC24-hPAH the dimer represented the major oligomeric
form (Fig. 3A). SDS-PAGE of this fraction (peak 3) revealed one
distinct band at ~96 kDa (StrepII-MBP-WT-hPAH) and another at
~82 kDa (6His-MBP-ΔN102/ΔC24-hPAH) of different intensities, as
the double truncated form assembles as dimers with a higher
solubility (Fig. 3A, inset, lane 3). SDS-PAGE of the tetrameric fraction
(peak 2) gave a single band of ~96 kDa (Fig. 3A, inset, lane 2)
corresponding to the StrepII-MBP-WT-hPAH protein. For the co-
expressed StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH, the
tetramers were the predominant species (Fig. 4A) with 96 and 84 kDa
bands on SDS-PAGE (Fig. 4A, inset, lane 2), corresponding to the
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH, respectively.
The dimeric fraction corresponding to the WT-hPAH (Fig. 4A, inset,
lane 3), revealed a band corresponding to the truncated form, since
the dimeric fraction (peak 3) was not completely resolved from the
ΔN102-hPAH tetramer.
3.2. Study of the heterodimer and heterotetramer formation using WT
and truncated forms of hPAH
3.2.1. (WT)/(ΔN102/ΔC24)-hPAH heterodimer is not formed
When the dimeric fraction of the co-expressed StrepII-MBP-WT-
hPAH and 6His-MBP-ΔN102/ΔC24-hPAH was applied to the Ni–NTA
resin, a protein with an apparent molecular mass of ~96 kDa,
corresponding to the StrepII-MBP-WT-hPAH subunit, was recovered
in the ﬂow-through (Fig. 3B, lane 2). Only a trace amount of a ~82 kDa
protein was observed, corresponding to the 6His-MBP-ΔN102/ΔC24-
hPAH, indicating that homodimeric StrepII-MBP-WT-hPAH was
mainly obtained in the ﬂow-through. Elution of bound proteins
with imidazole gave essentially one band at 82 kDa (Fig. 3B, lane 3),
suggesting that only the 6His-MBP-ΔN102/ΔC24-hPAH species was
recovered. In fact, when this fraction was applied to the Strep-Tactin
resin (Fig. 3C) a band corresponding to the 6His-MBP-ΔN102/ΔC24-
Fig. 3. Isolation and SDS-PAGE analysis of heterodimeric StrepII-MBP-WT-hPAH/6His-MBP-ΔN102/ΔC24-hPAH proteins. (A) Size-exclusion chromatography of the co-expressed
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102/ΔC24-hPAH with three main peaks: (1) aggregated forms; (2) tetramers; and (3) dimers. The inset panel represents the SDS-PAGE
analysis demonstrating the purity of the proteins eluted as tetramers (lane 2) and dimers (lane 3). The fraction with the double arrow between the two dashed lines indicates the
collected dimers used in the further puriﬁcation steps. (B) SDS-PAGE analysis of Ni–NTA puriﬁcation. Lane 1, dimeric fraction from (A) applied on the Ni–NTA chelating resin; lane 2,
ﬂow-through containing StrepII-MBP-WT-hPAH homodimers (subunit Mr of ~96 kDa); lane 3, 150 mM imidazole eluted fraction containing 6His-MBP-ΔN102/ΔC24-hPAH
homodimers (subunit Mr of ~82 kDa) and the potential StrepII-MBP-WT-hPAH/6His-MBP-ΔN102/ΔC24-hPAH heterodimers (subunits Mr of ~96 and ~82 kDa, respectively). (C)
SDS-PAGE analysis of the Strep-Tactin puriﬁcation. Lane 1, ﬂow-through containing 6His-MBP-ΔN102/ΔC24-hPAH homodimers; lane 2, desthiobiotin eluted fraction after acetone-
precipitation (see main text for further explanation — Results section). Lane M, low-molecular-mass marker (104.4, 83.2, 49.3, 36.9 and 28.9 kDa). At the bottom of each lane is
indicated the expected hPAH forms as depicted in Fig. 2, with the StrepII-MBP-WT-hPAH polypeptide chain (□) and the 6His-MBP-ΔN102/ΔC24-hPAH polypeptide chain (○).
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ﬂow-through (Fig. 3C, lane 1), and only negligible amounts of
recombinant 82 kDa and 96 kDa fusion proteins were eluted with
desthiobiotin (Fig. 3B, lane 2). This fraction was acetone-precipitated,
and the recovered proteins, representing less than 1% of the
homodimeric proteins, may correspond to proteins that remained
bound to the column from the previous steps of puriﬁcation. The
results indicate that only StrepII-MBP-WT-hPAH and 6His-MBP-
ΔN102/ΔC24-hPAH homodimers, but no StrepII-MBP-WT-hPAH/
6His-MBP-ΔN102/ΔC24-hPAH heterodimers, were formed.3.2.2. The (WT)/(ΔN102)-hPAH heterotetramer
The His-tag afﬁnity puriﬁcation of the co-expressed StrepII-MBP-
WT-hPAH and 6His-MBP-ΔN102-hPAH proteins resulted in the
recovery of the StrepII-MBP-WT-hPAH homotetramer (~96 kDa
subunit) in the ﬂow-through when applied to the Ni-chelating resin
(Fig. 4B, lane 2), and the imidazole elution recovered the StrepII-MBP-
WT-hPAH (~96 kDa) and 6His-MBP-ΔN102-hPAH (~84 kDa), in a
~1:3 ratio (Fig. 4B, lane 3). Subsequent StrepII-tag afﬁnity puriﬁcation
of this fraction resulted in the recovery of the 6His-MBP-ΔN102-hPAH
homotetramer (~84 kDa subunit) in the ﬂow-through (Fig. 4C, lane
1), and the desthiobiotin elution recovered the heterotetramerStrepII-MBP-WT-hPAH/6His-MBP-ΔN102-hPAH, with two bands
(~96 and ~84 kDa subunit ) in a 1:1 ratio (Fig. 4C, lane 2).
3.3. Steady-state kinetic analysis of the (WT)/(ΔN102)-hPAH
heterotetramers
After cleavage of the fusion tags the steady-state kinetic parameters
of the tetrameric forms of WT-hPAH, ΔN102-hPAH and the (WT)/
(ΔN102)-hPAH heterotetramer were determined (Tables 3 and 4). The
factor Xa cleavage of the fusion proteins resulted in some unspeciﬁc
cleavage that generated a mixture of WT-hPAH full-length and ΔΝ13-
hPAH for the WT fusion protein [33]; and the cleavage of the ΔΝ102-
hPAH fusion protein generated the truncated form ΔN112-hPAH [34].
However, the kinetic properties of themixture of the full-lengthWT and
ΔΝ13-hPAH enzymes were similar to those of the full-length enzyme
in terms of cooperativity and substrate activation, with only the
phosphorylation of S16 by cAMP-dependent protein kinase being
affected [33]. The kinetic properties obtained for WT and ΔN102-
hPAH are in line with the reported values in the literature [2,33,34].
Whereas relatively small differences in the Km value for the cofactor
were observed between the three species (Table 4), marked differences
were observed for L-Phe in terms of concentration at half-maximal
activity ([S]0.5), catalytic efﬁciency, catalytic activationand cooperativity
Fig. 4. Isolation and SDS-PAGE analysis of heterotetrameric StrepII-MBP-WT-hPAH/6His-MBP-ΔN102-hPAH proteins. (A) Size-exclusion chromatography of the co-expressed
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH with four main peaks: (1) aggregated forms, (2) tetramers, (3) dimers; and (4) low-molecular protein degradation products
from the amylose puriﬁcation (see Fig. 2). The inset panel represents the SDS-PAGE analysis of isolated protein from each peak in the elution proﬁle, tetramers (lane 2), dimers (lane
3) and degradation products (lane 4). The fraction with the double arrow between the two dashed lines indicates the collected tetramers used in the further puriﬁcation steps.
(B) SDS-PAGE analysis of the Ni–NTA resin puriﬁcation. Lane 1, tetrameric fraction from SEC applied on the Ni–NTA resin; lane 2, ﬂow-through containing StrepII-MBP-WT-hPAH
homotetramers (subunit Mr of ~96 kDa) (3); lane 3, 150 mM imidazole eluted fraction containing 6His-MBP-ΔN102-hPAH homotetramers (subunit Mr of ~84 kDa) and StrepII-
MBP-WT-hPAH/6His-MBP-ΔN102-hPAH heterotetramers (subunits Mr of ~96 and ~84 kDa, respectively). (C) SDS-PAGE analysis of Strep-Tactin puriﬁcation. Lane 1, ﬂow-through
containing 6His-MBP-ΔN102-hPAH homotetramers; lane 2, desthiobiotin eluted fraction containing StrepII-MBP-WT-hPAH/6His-MBP-ΔN102-hPAH heterotetramers. Lane M, low-
molecular-mass marker (104.4, 83.2, 49.3, 36.9 and 28.9 kDa). At the bottom of each lane is indicated the expected hPAH forms as depicted in Fig. 2, with the StrepII-MBP-WT-hPAH
polypeptide chain (□) and the 6His-MBP-ΔN102-hPAH polypeptide chain (○).
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a lower [S]0.5 (L-Phe) value (76±17 μM) than the WT-hPAH homo-
tetramer ([S]0.5=151±6 μM), but only slightly higher than the
truncated homotetramer ΔN102-hPAH ([S]0.5=55±3 μM) (Table 3).
The heterotetramer is also characterized by a marked decrease in the
kcat (0.34±0.03×103 nmol Tyr⋅min−1⋅nmol tetramer−1), a value
lower than that predicted by averaging the kcat of the homotetramericTable 3
Steady-state kinetic constants for the substrate (L-Phe) of WT-hPAH homotetramer, ΔN102
hPAH Vmax kcat kcat (PRA) Vi
103 nmol
Tyr⋅min−1⋅mg−1
103 nmol
Tyr⋅min−1⋅nmol−1
103 nmol
Tyr⋅min−1⋅mg−
WT 2.79±0.07 0.56±0.01 − 1.55±0.14
ΔN102 10.4±0.27 1.68±0.04 − 4.53±0.27
(WT)/(ΔN102) 1.85±0.18 0.34±0.03 1.12 1.03±0.05
The catalytic activity was measured as described in the Materials and methods section at 25 °
activity and kcat/[S]0.5 the catalytic efﬁciency which was calculated on the basis of the tetram
(ΔN102)-hPAH, respectively. PRA, predicted residual activity of the heterotetramer, is the mcounterparts (kcat,PRA=1.12×103nmol Tyr⋅min−1⋅nmol tetramer−1)
(Table 3).Moreover, the (WT)/(ΔN102)-hPAHheterotetramer revealed
no kinetic cooperativity (nH=1.0±0.1)with respect to L-Phe and is not
activated by L-Phe preincubation (1.1-fold), properties also observed for
the truncated homotetramerΔN102-hPAH (nH=1.2±0.1 and 1.0-fold,
respectively). By contrast the WT-hPAH homotetramer revealed a
kinetic positive cooperativity (nH=2.1±0.1) and a 3.6-fold activation-hPAH homotetramer and (WT)/(ΔN102)-hPAH heterotetramer.
[S]0.5 Ki kcat/[S]0.5 nH Fold activation
R(ν+L-Phe/ν− L-Phe)
1
μM mM μM−1⋅min-1
151±6 2.20±0.44 4 2.1±0.1 3.6
55±3 1.56±0.17 30 1.2±0.1 1.0
76±17 0.86±0.23 4 1.0±0.1 1.1
C, 75 μM BH4 (L-Phe variable). [S]0.5 represents the L-Phe concentration at half-maximal
er molecular mass of 200, 161.2 and 180.6 kDa for WT-hPAH, ΔN102-hPAH and (WT)/
ean of the kcat of the corresponding homotetramers.
Table 4
Steady-state kinetic constants for the cofactor (BH4) of WT-hPAH homotetramer,
ΔN102-hPAH homotetramer and (WT)/(ΔN102)-hPAH heterotetramer.
hPAH Vmax kcat kcat (PRA) Km
103 nmol
Tyr⋅min−1⋅mg−1
103 nmol
Tyr⋅min−1⋅nmol−1
μM
WT 2.83±0.08 0.57±0.02 − 27±3
ΔN102 10.1±0.44 1.63±0.07 − 39±5
(WT)/(ΔN102) 1.44±0.05 0.26±0.01 1.10 24±3
The catalytic activity was measured as described in the Materials and methods section
at 25 °C, 1 mM L-Phe (BH4 variable). PRA, predicted residual activity.
Fig. 5. The effect of substrate (L-Phe) concentration on the catalytic activity of the
heterotetrameric (WT)/(ΔN102)-hPAH protein and homotetrameric counterparts. The
hPAH activity was assayed at standard conditions (0–4 mM L-Phe, 75 μM BH4 and
25 °C) for the isolated homotetrameric WT-hPAH (A), homotetrameric ΔN102-hPAH
(B) and heterotetrameric (WT)/(ΔN102)-hPAH (C). The insets represent the data
obtained in the concentration range 0–500 μM L-Phe. The kinetic constants are
summarized in Table 3.
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was 4 μM−1⋅min−1 for both the heterotetrameric form andWT-hPAH.
3.4. Limited proteolysis of (WT)/(ΔN102)-hPAH heterotetramer with
trypsin
On limited proteolysis by trypsin, the WT-hPAH homotetramer
(Fig. 6A) was found to be more resistant than the homotetrameric N-
terminal truncated form both in the absence and presence of L-Phe
(Fig. 6B). A small proteolytic fragment is rapidly cleaved off in the
ΔN102-hPAH homotetramer, during the ﬁrst 10 min of incubation,
generating a core fragment of ~35 kDa resistant to further trypsin
proteolysis. A core fragment of similar molecular mass was also
obtained from the WT-hPAH trypsin proteolysis (data not shown).
Whereas the WT-hPAH became markedly more susceptible to limited
proteolysis in the presence of L-Phe, only a slight increase in the rate of
proteolysis was observed for the truncated form (Fig. 6A and B).While
the heterotetrameric (WT)/(ΔN102)-hPAH revealed no signiﬁcant
difference in the rate of proteolysis for the ΔN102-hPAH protomer
(Fig. 6D), the WT protomer is more rapidly degraded (Fig. 6C).
4. Discussion
4.1. The developed bicistronic expression system is a valuable tool to
produce and isolate heteromeric forms of hPAH
Co-expression of different proteins in E. coli can be achieved using
three different strategies: (i) a multi-vector expression system (e.g.
dual vector system with plasmids with different replication origins
and selection markers and with identical or different promoters), (ii)
a single polycistronic plasmid with a single promoter, encoding a long
polycistronic mRNA, and (iii) a single polycistronic plasmid with
individual promoters [46]. In our previous work [14] we followed the
ﬁrst strategy but the low yield preclude the isolation of the hybrid
species. Since the use of the second strategy (one polycistronic vector
with a single promoter) has been reported to lead to a lower
expression of themore downstream encoded protein [47], we decided
to follow the third strategy. Using a bicistronic vector with individual
but identical promoters (T7 promoter) and two terminators, we
obtained similar and high expression levels of both proteins. By using
a single plasmid we also assured that the two proteins should localize
within the same region of the cell, in contrast to replication from
different plasmids which could have a different subcellular localiza-
tion within the bacterium [48]. Additionally, due to expression from
two similar sequences, veriﬁcation of plasmid integrity is necessary to
rule out homologous recombination, as E. coli BL21(DE3) (recA+
strain) is one of the most commonly used expression strains.
Alternatively, a recA− derivative of BL21 should be used (e.g. BLR
(DE3) [49]).
In the present work the hPAH variants (WT and truncated forms)
were recognized by their different molecular mass. In studies on
missense mutations, the detection and quantiﬁcation can readily be
achieved by immuno-detection with monoclonal antibodies speciﬁcfor the epitope tags (hexahistidyl peptide and StrepII peptide) andMS
peptide analyses. Moreover, the depicted vector can be easily adapted
to an in vitro transcription-translation system (the large tags can be
removed and a consensus Kozak sequence introduced at theMCS2), as
a potential tool to study the observed inconsistencies in BH4
supplementation (see below).
4.2. The formation of hPAH heteromers occurs by a non-random
assembly process
The C-terminal oligomerization domain of WT-hPAH (residues
412–452) consists of two short β-strands (Ser411-Tyr414 and Ile421-
Leu424), connected by a loop (residues 415–420), and a 40 Å long α-
helix (Gln428-Lys452). Dimerization is mediated by several van der
Fig. 6. Time-course for the limited proteolysis of the heterotetrameric (WT)/(ΔN102)-hPAH protein and homotetrameric counterparts by trypsin. The susceptibility to trypsin
proteolysis ofWT-hPAH homotetramer (● and○) and ΔN102-hPAH homotetramer (▲ and△) is shown in panels A and B, respectively. In C and D, the proteolysis patterns of theWT
(● and○) andΔN102 (▲ and△) protomers of the heterotetrameric (WT)/(ΔN102)-hPAH are shown, respectively. Limited proteolysis was performed in the absence (ﬁlled symbols,
● and▲) or presence (open symbols, ○ and△) of 1 mM L-Phe at a protease/hPAH ratio of 1:200 (by mass). At time interval aliquots were mixed with soybean trypsin inhibitor and
subjected to SDS-PAGE, and the band corresponding to the remaining full-length protein was quantiﬁed (WT subunit: ~50 kDa and ΔN102 subunit: ~38.8 kDa). The data were ﬁtted
to a single exponential decay curve. The recovery of the full-length WT-hPAH protomer in the heterotetramer at t~20 min, in the absence of L-Phe, is practically the same as in the
WT-hPAH homotetramer in the presence of L-Phe.
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loops (residues 415–420), one of each protomer [1,50], and through a
relatively polar interface contributed by the regulatory domain in one
protomer and the catalytic domain in the other protomer [51].
In the present study, the co-expression of WT-hPAH and truncated
forms of the protein allowed the isolation of heterotetramers,
resulting from the assembly of different homodimers (2hPAH1/
2hPAH2), but no heterodimers were recovered. Thus, the absence of
a random assortment of hPAH protomers suggests that hPAH
dimerization, via the Asp415-Arg420 loop of the dimerization motif,
is a co-translational process and that tetramer formation (dimer of
dimers) occurs post-translationally. Tetramerization occurs from
preformed dimers through domain swapping of the C-terminal α-
helices (Gln428-Lys452) [1], and our data indicate that these
interactions will not be affected by the presence of two different
stable dimers with a WT like C-terminal α-helix structure. A co-
translational assembly of dimers could explain why hPAH monomers
were never found for WT-hPAH [34] or in mutant forms, except for
Y417Hmapped to the dimerization motif preventing the formation of
dimers [52].
4.3. The WT protomer within the heterotetramer reveal conformational
changes
Binding of L-Phe at the active site triggers reversible conforma-
tional changes in the catalytic domain [53], which are transmitted
globally (dimer and tetramer) through several hinge-bending regions[53–56] resulting in a more open structure [54]. This conformational
change results in an increased susceptibility to limited proteolysis by
trypsin (Fig. 6A). The WT protomer revealed a higher susceptibility to
limited proteolysis when present in the heterotetrameric (WT)/
(ΔN102)-hPAH than in the homomeric form, both in the absence and
presence of L-Phe, indicating that the WT protomer adopts a more
open conformation. These results suggest that the assembly of the two
different dimers (WT and ΔN102) induces a conformational change in
the WT protomers mediated by the C-terminal 40-Å long α-helix
(Gln428-Lys452), as the only contact between the two dimers in the
assembled tetramer occurs by domain swapping of the four C-
terminal helices (two from each dimer) [1].
4.4. Functional implications of the assembly of hPAH heterotetramers
A comparison of the steady-state kinetic parameters of the (WT)/
(ΔN102)-hPAH heterotetramer with the homotetrameric counter-
parts (Table 3) revealed that the heterotetramer has acquired a
catalytic efﬁciency similar to that of WT-hPAH. However, it has lost
the cooperativity with respect to L-Phe and the ability to be activated
by the substrate, which are characteristic properties of the ΔN102-
hPAH tetramer. Moreover, the Vmax-value was only ~30% of the
predicted residual activity (PRA), thus demonstrating a negative
interallelic complementation. However, it should be noted that the
isolatedWT-hPAH dimeric form revealed no kinetic cooperativity and
only aminor fold activation by L-Phewhen compared to theWT-hPAH
tetramer [4], and the kinetic properties of the isolated ΔN102-hPAH
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tetramers (Table 2). If the two dimers in the heterotetramer were
acting isolated, the lack of cooperativity and substrate activation in
the hybrid could be explained. However, the L-Phe concentration at
half-maximal activity ([S]0.5) of the WT-hPAH dimeric form is much
higher than the WT-hPAH tetramer [4], whereas the hybrid tetramer
displays a [S]0.5 (L-Phe) lower than the WT-hPAH tetramer. Taking
these results into consideration and the ones obtained from the
trypsin limited proteolysis, indicating that the WT dimer in the
heterotetramer underwent a conformational change, it was not
unexpected to ﬁnd that the catalytic properties of the heterotetramer
were consistently different from those obtained theoretically by
averaging the homomeric counterparts. The fact that the presence of
two homodimers with different kinetic parameters can alter the
properties of resulting hybrid protein indicates that interactions are
transmitted across the overall assembled protein and that the dimers
are not acting isolated.
4.5. Implications of heterotetrameric assembly in PKU
Although the mutant partner used in the present study is a
truncated protein and not a PKU-mutant enzyme, the results obtained
in this work can give some insight into the mechanisms involved in
PKU, as we report here the ﬁrst isolation of a heterotetrameric form of
hPAH with properties deviating signiﬁcantly from the average of
those of the parental enzymes. The developed expression/puriﬁcation
strategy provides the necessary experimental tools for studies on
disease-associated hPAH mutations, notably those demonstrating
inconsistencies both in genotype/phenotype correlations and in the
response to BH4 supplementation. The mechanisms underlying BH4-
responsiveness are multifactorial, including correction of catalytic
defect (decreased afﬁnity for BH4) and stabilization of the mutant
protein against degradation/inactivation in vivo and in vitro [57–59].
Until now, in vitro studies to unravel the mechanism of BH4-
responsiveness (e.g. steady-state kinetic analysis, isothermal titration
calorimetry and thermostability followed by circular dichroism
spectroscopy) have been limited to the study of homotetrameric
proteins. However, they do not represent the hPAH protein
population of a compound heterozygous patient. The isolation of the
heterotetramers will allow the in vitro characterization of these
species in terms of the cofactor effect. However, one limitation of the
prokaryotic expression system is that it is not amenable to test the
effect of precise BH4 concentrations when the protein assembles in
vivo. One alternative is to use the described system (with minor
modiﬁcations) in an in vitro transcription–translation expression
system. It will be important to understand how the mutations alter
the observed 2hPAH1:2hPAH2 association of hPAH dimers and if they
also exert a dominant negative impact on the function of the
heteromeric species. As a large fraction of PKU mutations affects
stability and/or folding efﬁciency, this system will also be a valuable
tool to understand how an aggregation-prone mutant (e.g. G46S
[30,60]) affects the other mutant partner within the heteromeric
protein.
The characterization of the interactions between wild-type and
mutant dimers and between different mutant dimers (compound
heterozygous) is clinically relevant, as they will contribute to a better
understanding of the metabolic phenotype in the HPA/PKU patients
and BH4-responsiveness. It will also be essential in the development
of new emerging therapies (e.g. pharmacological chaperones), as the
hybrid proteins could respond differently from the parental enzymes.
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